《績後表現》石藥(01093.HK)首季多賺22%擬於滬科創板上市 股價午後抽升近7%撲百天線
藍籌石藥(01093.HK)首季多賺近22%及計劃上交所科創板上市,該股下午開市扭轉半日倒跌勢,逆市抽升6.8%報16.96元,股價重越牛熊線(16.22元),直逼百天線(17.06元),逆市三連漲,成交增至3,393萬股,涉資5.56億元。
石藥公布,首季純利按年升21.8%至11.59億元人民幣(下同),毛利按年升近18%至45.29億。期內,總營收按年升11.5%至61.25億元,其中成藥收入按年升18.3%至50.22億元。集團透露,未來三年預計將上市新產品超過50個,其中預計市場空間超過10億元重磅品種將不少於15個,可強力支撐集團未來的高質量增長。
另外,石藥董事會批准可能進行人民幣股份或中國存托憑證發行,並於上交所科創板上市初步建議,有待股東大會及監管當局批准。
恆指現造23,220,跌164點或0.7%,成交額698億元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.